If the secretary of Health and Human Services truly wants to solve America’s obesity crisis, he must understand that ...

Tv Therapeutics' Phase 3 trial for cadisegliatin in type 1 diabetes resumes after FDA lifts hold, with a revised six-month ...

WEIGHT loss jabs have become the latest fad for changing your appearance. It seems as though half of Hollywood is using ...

What are the key medical considerations for people with diabetes who wish to fast during Ramadan and how can they assess ...

For Maria Rising, managing her health felt like chasing a phantom. The 30-year-old Lansing, Mich. consultant has for years ...

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes. CATT1 Phase 3 trial expected to ...

Growth hormone injections deliver a synthetic growth hormone to the body to treat hormone deficiencies and other health ...

Amid the soaring use of glucagon-like peptide-1 (GLP-1) drugs for intentional weight loss, a vastly different movement appears to be gaining traction in health care: Many clinicians are pushing for a ...

Cadisegliatin has the potential to be the first oral adjunct therapy for type 1 diabetes CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall durati ...

Ang, a Las Vegas-based 23-year-old parent program supervisor and social work grad student, began to experience dry skin, but ...

Discover the causes behind fatty liver disease, a condition affecting 25% of adults worldwide, and learn simple lifestyle ...

Investing.com -- Shares of vTv Therapeutics Inc . (NASDAQ: VTVT) rose 15% after the company announced that the FDA has lifted the clinical hold on its Cadisegliatin program for diabetes. Trading had ...